Sodium-glucose Cotransporter 2 Inhibitor Use: A Pharmaco-ergonomic Qualification Tool.
作者信息
Kalra Sanjay, Unnikrishnan A G, Baruah Manash, Kawatra Pallavi, Ved Jignesh
机构信息
Director, Bharti Hospital and BRIDE, Karnal, Haryana, India.
Director, Chellaram Diabetes Institute, Pune, Maharashtra, India.
出版信息
Indian J Endocrinol Metab. 2017 Sep-Oct;21(5):762-764. doi: 10.4103/ijem.IJEM_184_17.
Abstract
Pharmaco-ergonomics implies tailoring the drug therapy to an individual patient's requirement(s). The development of sodium-glucose cotransporter 2 inhibitor (SGLT2-i) agents has impelled multiple clinical considerations, in the management of type-2 diabetes. This paper attempts to summarize the pharmaco-ergonomic considerations for these agents, in the form of an SGLT2-i qualification tool, based on a clinical score. This tool may serve as a simple and inexpensive practical guide, to optimize the risk-benefit considerations for SGLT2-i agents.
摘要
相似文献
1
Sodium-glucose Cotransporter 2 Inhibitor Use: A Pharmaco-ergonomic Qualification Tool.
Indian J Endocrinol Metab. 2017 Sep-Oct;21(5):762-764. doi: 10.4103/ijem.IJEM_184_17.
2
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.SGLT2抑制剂的基础与临床药物治疗学：当代最新进展
Diabetes Ther. 2020 Apr;11(4):813-833. doi: 10.1007/s13300-020-00789-y. Epub 2020 Mar 4.
3
Clinical use of dipeptidyl peptidase-4 and sodium-glucose cotransporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.二肽基肽酶-4抑制剂与钠-葡萄糖协同转运蛋白2抑制剂在2型糖尿病联合治疗中的临床应用
Postgrad Med. 2015 Jun;127(5):463-79. doi: 10.1080/00325481.2015.1044756. Epub 2015 May 8.
4
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents.天然产物来源的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：新一代降血糖药物的发现
Molecules. 2016 Aug 27;21(9):1136. doi: 10.3390/molecules21091136.
5
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity.钠-葡萄糖协同转运蛋白2抑制剂对交感神经活动的影响。
Front Endocrinol (Lausanne). 2018 Jul 26;9:421. doi: 10.3389/fendo.2018.00421. eCollection 2018.
6
An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients.钠葡萄糖协同转运蛋白2抑制剂单药治疗对2型糖尿病患者血糖及其他临床实验室参数影响的综述
Ther Clin Risk Manag. 2016 Jul 15;12:1113-31. doi: 10.2147/TCRM.S112236. eCollection 2016.
7
Positioning of sodium-glucose cotransporter-2 inhibitors in national and international guidelines.钠-葡萄糖协同转运蛋白2抑制剂在国内和国际指南中的定位
Med Clin (Barc). 2016 Nov;147 Suppl 1:49-53. doi: 10.1016/S0025-7753(17)30626-7.
8
Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.与钠-葡萄糖协同转运蛋白2抑制剂使用相关的正常血糖性糖尿病酮症酸中毒：一例病例报告及文献综述
Int J Emerg Med. 2019 Sep 5;12(1):27. doi: 10.1186/s12245-019-0240-0.
9
Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level.舍格列净是一种新型的低亲和力钠-葡萄糖协同转运蛋白2（SGLT2）选择性抑制剂，证实了SGLT2在肾脏葡萄糖重吸收中的关键作用，并调节血糖水平。
J Pharmacol Exp Ther. 2007 Jan;320(1):323-30. doi: 10.1124/jpet.106.110296. Epub 2006 Oct 18.
10
Emerging roles of sodium-glucose cotransporter 2 inhibitors in cardiology.钠-葡萄糖协同转运蛋白2抑制剂在心脏病学中的新作用
J Cardiol. 2017 Mar;69(3):501-507. doi: 10.1016/j.jjcc.2016.10.019. Epub 2016 Dec 30.
引用本文的文献
1
Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update.SGLT2抑制剂的基础与临床药物治疗学：当代最新进展
Diabetes Ther. 2020 Apr;11(4):813-833. doi: 10.1007/s13300-020-00789-y. Epub 2020 Mar 4.
本文引用的文献
1
Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.2型糖尿病中钠-葡萄糖协同转运蛋白2抑制剂的安全务实应用：南亚内分泌学会联盟共识声明
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):210-230. doi: 10.4103/2230-8210.196029.
2
Is Hemoglobin A1c the Right Outcome for Studies of Diabetes?糖化血红蛋白（HbA1c）是糖尿病研究的恰当结局指标吗？
JAMA. 2017 Mar 14;317(10):1017-1018. doi: 10.1001/jama.2017.0029.
3
Are Diabetes Care Providers Too Glucocentric?糖尿病护理提供者是否过于以葡萄糖为中心？
Can J Diabetes. 2016 Dec;40(6):479-481. doi: 10.1016/j.jcjd.2016.10.004. Epub 2016 Oct 31.
4
Sodium glucose co-transporter 2 inhibitors in patients with resistant hypertension: a case study.钠-葡萄糖协同转运蛋白2抑制剂用于难治性高血压患者：一项病例研究
JRSM Open. 2016 Sep 1;7(9):2054270416649285. doi: 10.1177/2054270416649285. eCollection 2016 Sep.
5
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.恩格列净：在 2 型糖尿病中的心血管结局和死亡率。
N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17.
6
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.钠-葡萄糖协同转运蛋白2抑制剂与心血管风险：提出的作用途径及正在进行的结局试验综述
Diab Vasc Dis Res. 2015 Mar;12(2):90-100. doi: 10.1177/1479164114559852. Epub 2015 Jan 14.
Zotero 插件